About Elbion
Elbion is a company based in Radebeul (Germany) founded in 2002 was acquired by Biotie in November 2008. Elbion has raised $45 million across 1 funding round from investors including 3i Group, Biotie and Burrill and Company. Elbion has completed 1 acquisition, including DrugAbuse Sciences.
- Headquarter Radebeul, Germany
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Elbion
Elbion has successfully raised a total of $45M through 1 strategic funding round. The most recent funding activity was a Series A round of $45 million completed in January 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Elbion
Elbion has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include 3i Group, Biotie and Burrill and Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on mid-market businesses
|
Locked | Locked | Locked | |
|
Multi-category products are listed on an online B2B platform.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Elbion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Elbion
Elbion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include DrugAbuse Sciences.
Investment portfolio details for Elbion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for alcohol and drug addictions are developed and commercialized.
|
Locked | Locked | 1994 | Locked |
Complete acquisition details for Elbion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Elbion
Detailed financials for Elbion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Elbion Comparisons
Peer comparison for Elbion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Elbion
Detailed competitors of Elbion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Elbion
Complete news archive for Elbion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elbion
Elbion was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Elbion is headquartered in Radebeul, Germany. It is registered at Radebeul, Saxony, Germany.
Elbion is a funded company, having raised a total of $45M across 1 funding round to date.
Elbion was focussed on the discovery of small molecules against inflammatory and CNS diseases. Its drug discovery activities were focused on PDE inhibitors, adenosine antagonists and potassium channel modulators. It was co-developing its lead product, AWD 12-281 along with GSK for COPD and for atopic dermatitis. It was also developing ELB139, a subunit-specific GABA(A) agonist for the anxiety disorders and ELB353 for inflammatory diseases. In October 2008, Biotie acquired Elbion.
Elbion has made 1 acquisition, including DrugAbuse Sciences.
Elbion has 4 investors. Key investors include 3i Group, Biotie, Burrill and Company, and Deutsche Venture Capital.